- **2026 Design Freeze On Track**: Despite 15% workforce reduction, maintaining clinical trial timelines via targeted outsourcing.
- **$10M+ Annualized Cost Savings**: 35% YoY expense reduction, with 2026 burn target <$40M.
- **Surgeon-Tested Efficiency**: 65% reduction in complex surgical procedures, validating commercial viability.
- **Transparency Boost**: Weekly LinkedIn updates to replace quarterly earnings calls for real-time progress.

**【CEO Summary Section】**
- **Design Freeze Milestone**: Targeting completion of production-equivalent system by end-2026, with focus on maintaining clinical trial and commercialization timelines despite restructuring efforts.
- **Cost Reduction Strategy**: 15% headcount reduction across non-core functions, engaging PA Consulting for outsourcing RFPs to reduce 2026 cash burn by ~$10M+.
- **Transparency Initiative**: Launching weekly LinkedIn updates on control builds (e.g., PDV2 progress), quality management system implementation, and surgeon testing results (e.g., 65% reduction in IPOM hernia suturing time from 40min to 14min).

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: 
  - Total operating expenses: $11.5M (35% YoY decline)
  - GAAP net loss: $11.1M ($1.86/share) vs. $17.1M ($2.90/share) prior year
  - Cash burn rate: $10.5M/Q3, with $5.9M raised in Oct registered direct offering
- **Expense Optimization**: R&D down 28% YoY, G&A down 45%, sales & marketing down 71%.

**【Q&A Key Highlights】**
- **Outsourcing Impact**: Consulting engagement to complete by end-Nov, with RFPs for capital equipment outsourcing to begin Q1 2026.
- **Surgeon Testing Success**: 10+ surgeons tested system stability, with dramatic improvement in suturing efficiency (40min → 14min).
- **Hospital Partnerships**: Strong engagement with health systems, with surgeons requesting hands-on demos post-commercialization.

Vicarious Surgical Inc. (RBOT) Q3 2025 Earnings Call Transcript

- **Strategic Shift**: Delayed FCU trial to prioritize production-ready system development, expected to enhance long-term commercial success.
- **Financial Discipline**: 24% YoY expense reduction to $13.5M, with $24M cash on hand and $50M annual cash burn guidance.
- **Leadership Transition**: New CEO Stephen From focuses on technical excellence and resource optimization.
- **Assessment Period**: 4-6 week evaluation to determine system readiness and revised clinical timelines.

**【Management Opening Remarks】**
- Adam Sachs introduced Stephen From as the new CEO, emphasizing his experience in healthcare and med tech. Sachs transitioned to President, focusing on product development and clinical programs.
- The company is undergoing a strategic shift to prioritize completing a production-equivalent robotic surgery system over near-term clinical trials.

**【CEO Commentary】**
- Stephen From highlighted the need to finalize a production-ready system for full verification, delaying the first clinical use (FCU) trial beyond 2025.
- A 4-6 week assessment will evaluate system readiness, with resources redirected from non-production testing to ensure commercial viability.
- The shift aims to avoid resource diversion and focus on long-term value through a robust, scalable system.

**【CFO Financial Commentary】**
- Q2 2025 operating expenses decreased 24% YoY to $13.5M, driven by reduced R&D (-16%), G&A (-28%), and sales (-75%).
- GAAP net loss was $13.2M, with cash reserves of $24M and full-year cash burn guidance of $50M.
- The company maintains disciplined spending to support strategic priorities.

**【Q&A Highlights】**
- **Clinical Trial Delay**: Postponing FCU to focus on production readiness; no material cash impact from trial preparation.
- **Resource Allocation**: Shift to system verification aims to reduce future costs and improve commercial success odds.
- **Milestones**: Assessment period will clarify timelines for system completion and subsequent clinical milestones.
- **Cash Position**: Current runway supports 2025 goals, with no immediate capital raise plans.


Vicarious Surgical (RBOT)-12 Aug 25-2025 Q2 Earnings call transcript

- **2025 Clinical Catalysts**: First human cases on track for late 2025, supported by completed instrument testing and mid-2025 regulatory filing.
- **Financial Discipline**: Q1 cash burn $12M vs. $50M annual target; exploring financing amid $37M cash balance and supportive investor base.
- **Strategic Leverage**: UMass partnership driving workflow optimization, with early collaboration accelerating pre-commercial adoption.

**【CEO Business Update】**
- **Clinical Milestone Progress**: First human cases expected in late 2025, with technical dossier submission mid-2025. Instrument sets for biocompatibility and sterility testing completed.
- **Strategic Partnerships**: Announced collaboration with UMass Memorial Medical Center to optimize perioperative workflows and surgeon education. Existing partnerships include HCA Healthcare, University Hospitals, and Intermountain Health.
- **Supply Chain Stability**: Overcame Q1 supply chain challenges, with no delays impacting Q1 milestones. Team confident in managing complex system components.

**【CFO Financial Review】**
- **Q1 2025 Financials**: Operating expenses $15.7M (2% YoY decrease). R&D: $9.4M, G&A: $5.3M, Sales & Marketing: $1M (flat YoY). Adjusted net loss $15.3M ($2.58/share), same as Q1 2024.
- **Cash Position**: $37M cash balance, Q1 cash burn $12M. Full-year 2025 cash burn expected at $50M. Evaluating financing options amid supportive investor base.

**【Q&A Key Takeaways】**
- **Funding Assurance**: Management prioritizing disciplined spending and exploring financing around upcoming milestones. Insider base remains supportive.
- **Regulatory Timeline**: Technical dossier submission mid-2025, with assumptions based on historical agency review times for similar devices. Anticipate potential back-and-forth but remain on track for 2025 first-in-human trials.
- **Partnership Impact**: UMass collaboration already informing workflow design, with focus on streamlined OR processes and surgeon training. Commercial benefits expected post-approval, but early collaboration accelerates adoption readiness.

Vicarious Surgical (RBOT)-12 May 25-2025 Q1 Earnings call transcript

- **V1.0 System Validation**: Successful Cadaver Lab testing confirms preclinical functionality, setting stage for late 2025 human trials.
- **Supply Chain Recovery**: Resolved component delays, but clinical trial start pushed to year-end 2025.
- **Financial Discipline**: 17% YoY operating expense reduction, $49M cash burn aligned with guidance.
- **Partnership Expansion**: New academic health network collaborations enhance clinical training and post-market validation capabilities.
- **Regulatory Momentum**: Ministry of Health dossier submission expected mid-2025, with FDA pre-submission collaboration ongoing.


**【Management Opening Remarks】**
- Kaitlyn Brosco introduced the call, highlighting the release of 2024 Q4 and full-year financial results.
- Reminder of forward-looking statements and associated risks, including regulatory approvals and financial performance uncertainties.

**【CEO Summary Section】**
- **V1.0 System Integration Success**: Completed Cadaver Lab testing, validating the V1.0 system's functionality and performance in preclinical settings.
- **Innovative Design Features**: Decoupled actuators enable single 18mm incision, 13 degrees of freedom per instrument, and advanced AI capabilities for future enhancements.
- **Hospital Partnerships**: Expanded partnerships with LSU Health New Orleans, Temple Health, and UI Health for clinical training and post-market evaluation.
- **Clinical Trial Timeline**: First human cases expected in late 2025, with pivotal trial启动后. Regulatory dossier submission to Ministry of Health anticipated mid-2025.
- **Supply Chain Challenges**: Delays with key suppliers impacted manufacturing, but resolved gated components; clinical trial inventory build progressing.

**【CFO Financial Commentary】**
- **Full-Year 2024 Financials**: Total operating expenses $66.6M (-17% YoY), R&D $40.2M (-15% YoY), G&A $21.9M (-19% YoY), Sales & Marketing $4.5M (-27% YoY).
- **Net Loss**: Adjusted net loss $63.3M ($10.75/share) vs. $76.3M ($15.67/share) in 2023.
- **Cash Management**: Cash burn $49M (aligned with guidance), ending 2024 with $49M in cash equivalents.
- **2025 Outlook**: Anticipated cash burn of ~$50M, with focus on strategic balance sheet reinforcement.

**【Q&A Key Highlights】**
- **Supply Chain Transparency**: Delays caused by sub-tier supplier financial issues resolved; no current gated components.
- **Clinical Trial Timing**: First human cases in late 2025; pivotal trial design to be finalized post-initial cases.
- **Regulatory Feedback**: Positive engagement with FDA under Safer Technologies program; sites express confidence in system and interest in post-approval adoption.
- **Manufacturing Progress**: Capital systems nearing completion; instruments in production, with cost improvements identified during testing.


Actual	-21.3	-4.5	-4.5	-4.8	-5.4	-4.8	-5.1	-4.8	-3.6	-2.1	-2.7	-2.86	-2.8766	-2.43	-2.58	-2.23	-1.91
Forecast	-1.8	-3.0925	-4.0878	-4.3808	-4.65	-5.2825	-4.05	-4.275	-4.214	-3.753	-2.85	-2.72	-2.575	-2.689	-2.48	-2.4967	-2.3267
Surprise	-1083.33%	-45.51%	-10.08%	-9.57%	-16.13%	+9.13%	-25.93%	-12.28%	+14.57%	+44.04%	+5.26%	-5.15%	-11.71%	+9.63%	-4.03%	+10.68%	+17.91%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

RBOT(Delisted)

RBOT fundamentals

RBOT Q3 2025 Earnings

Earnings Call

You can ask Aime